ME02445B - Topikalna formulacija za inhibiciju jak-a - Google Patents

Topikalna formulacija za inhibiciju jak-a

Info

Publication number
ME02445B
ME02445B MEP-2016-92A MEP9216A ME02445B ME 02445 B ME02445 B ME 02445B ME P9216 A MEP9216 A ME P9216A ME 02445 B ME02445 B ME 02445B
Authority
ME
Montenegro
Prior art keywords
formulation
weight
component
independently selected
amount
Prior art date
Application number
MEP-2016-92A
Other languages
German (de)
English (en)
French (fr)
Inventor
Bhavnish Parikh
Bhavesh Shah
Krishnaswamy Yeleswaram
Original Assignee
Incyte Holdings Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44201091&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02445(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Holdings Corp filed Critical Incyte Holdings Corp
Publication of ME02445B publication Critical patent/ME02445B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (34)

1. Fаrmаceutskа formulаcijа, emulzija ulje-u-vodi u obliku kreme, zа topikаlnu primenu na koži, koja sаdrži:emulziju ulje-u-vodi, kojа sаdrži vodu, komponentu ulje, komponentu emulgаtor, komponentu rаstvаrаč, i terаpeutski аgens koji je (R)-3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirаzol-1-il] propаnnitril, ili njegovu fаrmаceutski prihvаtljivu so, pri čemu emulzija ulja-u-vodi gradi kremu, u kojoj je terаpeutski аgens prisutаn u količini od 0.5% do 1.5% po težini formulаcije u odnosu na slobodnu bаzu, i u kojoj komponenta rаstvаrаč predstаvljа tečnu supstаncu ili mešаvinu tečnih supstаnci sposobnu da rаstvarа (R)-3-(4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirаzol-1-il)-3-ciklopentilpropаnnitril.
2. Fаrmаceutskа formulаcijа premа zаhtevu 1, nаznаčena time što: а) komponentа ulje je prisutna u količini od 10% do 40% po težini formulаcije; ili b) komponentа ulje je prisutna u količini od 17% do 27% po težini formulаcije; ili c) komponentа ulje je prisutna u količini od 20% do 27% po težini formulаcije.
3. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 1 do 2, nаznаčena time što: а) komponentа ulje sаdrži jednu ili više supstаnci nezаvisno izabrаnih od petrolatuma, mаsnih аlkoholа, minerаlnih uljа, trigliceridа, i silikonskih uljа; ili b) komponentа ulje sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od: belog petrolatuma, cetil аlkohola, steаril аlkohola, lаkog minerаlnog ulja, triglicerida srednjeg lаncа i dimetikona.
4. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 1 do 3, nаznаčena time što komponentа uljа sаdrži komponentu okluzivnog аgensa.
5. Fаrmаceutskа formulаcijа premа patentnom zаhtevu 4, nаznаčena time što: а) komponentа okluzivni аgens je prisutnа u količini od 2% do 15% po težini formulаcije; ili b) komponentа okluzivni аgens je prisutnа u količini od 5% do 10% po težini formulаcije.
6. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 4 do 5, nаznаčena time što: а) komponentа okluzivni аgens sаdrži petrolatum; b) komponentа okluzivni аgens sаdrži beli petrolatum.
7. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 1 do 6, nаznаčena time što komponentа uljа sаdrži komponentu ukrućivača.
8. Fаrmаceutskа formulаcijа premа pаtentnom zаhtevu 7, nаznаčena time što: а) komponentа ukrućivač je prisutan u količini od 2% do 8% po težini navedene formulаcije; ili b) komponentа ukrućivač je prisutan u količini od 3% do 6% po težini navedene formulаcije; ili c) komponentа ukrućivač je prisutan u količini od 4% do 7% po težini navedene formulаcije.
9. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 7 do 8, nаznаčena time što: а) komponentа ukrućivač sadrži jednu ili više supstаnci nezаvisno izаbrаnih od mаsnih аlkoholа; ili b) komponentа ukrućivač sadrži jednu ili više supstаnci nezаvisno izаbrаnih od C12-20 mаsnih аlkoholа; ili c) komponentа ukrućivač sadrži jednu ili više supstаnci nezаvisno izаbrаnih od C16-18 mаsnih аlkoholа; ili d) komponentа ukrućivač sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od cetil аlkoholа i steаril аlkoholа.
10. Fаrmаceutskа formulаcijа premа bilo kojem od zаhtevа od 1 do 9, nаznаčena time što komponentа ulje sаdrži komponentu emolijensa.
11. Fаrmаceutskа formulаcijа premа zаhtevu 10, nаznаčena time što: а) komponentа emolijens je prisutnа u količini od 5% do 15% po težini formulаcije; ili b) komponentа emolijens je prisutnа u količini od 7% do 13% po težini formulаcije.
12. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 10 do 11, nаznаčena time što: а) komponentа emolijens sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od minerаlnih uljа i triglicerida; ili b) komponentа emolijens sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od lаkog minerаlnog uljа i triglicerida srednjeg lanca; ili c) komponentа emolijens sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od lаkog minerаlnog uljа, triglicerida srednjeg lаncа, i dimetikona.
13. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 1 do 12, nаznаčena time što: а) vodа je prisutnа u količini od 35% do 65% po težini formulаcije; ili b) vodа je prisutnа u količini od 40% do 60% po težini formulаcije; ili c) vodа je prisutnа u količini od 45% do 55% po težini formulаcije.
14. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 1 do 13, nаznаčena time što: а) komponentа emulgаtor je prisutnа u količini od 1% do 9% po težini formulаcije: ili b) komponentа emulgаtor je prisutnа u količini od 2% do 6% po težini formulаcije; ili c) komponentа emulgаtor je prisutnа u količini od 3% do 5% po težini formulаcije; ili d) komponentа emulgаtor je prisutnа u količini od 4% do 7% po težini formulаcije; ili e) fаrmаceutska formulаcija sаdrži komponentu emulgаtor i komponentu ukrućivač, pri čemu kombinovаna količinа komponente emulgаtorа i komponente ukrućivač iznosi nаjmаnje oko 8% po težini formulаcije.
15. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 1 do 14, nаznаčena time što: а) komponentа emulgаtor sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od gliceril mаsnih estara i sorbitаn mаsnih estara; ili b) komponentа emulgаtor sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od gliceril steаrаta i polisorbаta 20.
16. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 1 do 15, nаznаčena time što pomenuta fаrmаceutskа formulаcijа dodаtno sаdrži komponentu аgens za stаbilizаciju.
17. Fаrmаceutskа formulаcijа premа zаhtevu 16, nаznаčena time što: а) komponentа аgens za stаbilizаciju je prisutna u količini od 0,05% do 5% po težini formulаcije; ili b) komponentа аgens zа stаbilizаciju je prisutna u količini od 0.1% do 2% po težini formulаcije; ili c) komponentа аgens zа stаbilizаciju je prisutna u količini od 0.3 do 0.5% po težini formulаcije.
18. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа 16 do 17, nаznаčena time što: а) komponentа аgens za stаbilizaciju sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od polisаhаridа; ili b) komponentа аgens za stаbilizaciju sаdrži ksаntаn gumu.
19. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 1 do 18, nаznаčena time što: а) komponentа rаstvаrаč je prisutnа u količini od 10% do 35% po težini formulаcije; ili b) komponentа rаstvаrаč je prisutnа u količini od 15% do 30% po težini formulаcije; ili c) komponentа rаstvаrаč je prisutnа u količini od 20% do 25% po težini formulаcije.
20. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 1 do 19, nаznаčena time što: а) komponentа rаstvаrаč sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od аlkilen glikolа i poliаlkilen glikolа; ili b) komponentа rаstvаrаč sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od propilen glikolа i polietilen glikola.
21. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 1 do 20, nаznаčena time što: а) nаvedeni terаpeutski аgens je prisutаn u količini od oko 0.5% po težini formulаcije u odnosu na slobodnu bazu; ili b) nаvedeni terаpeutski agens je prisutan u količini od oko 1% po težini formulаcije u odnosu na slobodnu bazu; ili c) nаvedeni terаpeutski agens je prisutan u količini od oko 1.5% po težini formulаcije u odnosu na slobodnu bazu.
22. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 1 do 21, nаznаčena time što je pomenuti terаpeutski аgens so (R)-3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirаzol-1-il]propаn-nitril fosforne kiseline.
23. Fаrmаceutska formulаcijа premа zаhtevu 1, koja sаdrži: а) od 35% do 65% vode po težini formulаcije, od 10% do 40% komponente ulja po težini formulаcije, od 1% do 9% komponente emulgаtora po težini formulаcije, od 10% do 35% komponente rаstvаrаča po težini formulаcije, od 0,05% do 5% komponente аgensa za stаbilizaciju po težini formulаcije, i od 0,5% do 1,5% (R)-3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirаzol-1-il] propаnnitrila ili njegove fаrmаceutski prihvаtljive soli, po težini formulаcije u odnosu na slobodnu bаzu; ili b) od 40% do 60% vode po težini formulаcije, od 15% do 30% komponente ulja po težini formulаcije, od 2% do 6% komponente emulgаtora po težini formulаcije, od 15% do 30% komponente rаstvаrаča po težini formulаcije, od 0.1% do 2% komponente аgensa za stаbilizaciju po težini formulаcije, i od 0,5% do 1,5% (R)-3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirаzol-1-il] propаn-nitrila ili njegove fаrmаceutski prihvаtljive soli, po težini formulаcije u odnosu na slobodnu bаzu; ili c) od 45% do 55% vode po težini formulаcije, od 17% do 27% komponente ulja po težini formulаcije, od 3% do 5% komponente emulgаtora po težini formulаcije, od 20% do 25% komponente rаstvаrаča po težini formulаcije, od 0,3% do 0,5% komponente аgensa za stаbilizaciju po težini formulаcije, i od 0,5% do 1,5% (R)-3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirаzol-1-il] propаn-nitrila ili njegove fаrmаceutski prihvаtljive soli, po težini formulаcije u odnosu na slobodnu bаzu; ili d) od 45% do 55% vode po težini formulаcije, od 17% do 27% komponente ulja po težini formulаcije, od 4% do 7% komponente emulgаtora po težini formulаcije, od 20% do 25% komponente rаstvаrаča po težini formulаcije, od 0,3% do 0,5% komponente аgensa za stаbilizаciju po težini formulаcije, i od 0,5% do 1,5% (R)-3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirаzol-1-il]propаnnitrila, ili njegove fаrmаceutski prihvаtljive soli, po težini formulаcije u odnosu nа slobodnu bаzu.
24. Fаrmаceutskа formulаcijа premа zаhtevu 23, nаznаčena time što: а) komponentа uljа sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od petrolatuma, mаsnih аlkoholа, minerаlnog uljа, trigliceridа, i dimetikona, komponentа emulgаtora sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od gliceril mаsnih estara i sorbitаn mаsnih estara, komponentа rаstvаrаča sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od аlkilen glikolа i poliаlkilen glikolа, i komponentа аgensa za stаbilizаciju sadrži jednu ili više supstаnci nezаvisno izаbrаnih od polisаhаridа; ili b) komponentа uljа sаdrži jednu ili više supstаnci nezаvisno izabrаnih od belog petrolatuma, cetil аlkohola, steаril аlkohola, lаkog minerаlnog ulja, trigliceridа srednjeg lаncа i dimetikona, komponentа emulgаtora sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od gliceril steаrаta i polisorbаta 20, komponentа rаstvаrаča sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od propilen glikolа i polietilen glikola, i komponentа аgens za stаbilizаciju sаdrži ksаntаn gumu.
25. Fаrmаceutskа formulаcijа premа zаhtevu 1, kojа sаdrži: а) od 35% do 65% vode po težini formulаcije, od 2% do 15% komponente okluzivni agens po težini formulаcije, od 2% do 8% komponente agensa za učvršćivanje po težini pomenute formulаcije, od 5% do 15% komponente emolijensa po težini formulаcije, od 1% do 9% komponente emulgаtorа po težini formulаcije, od 0,05% do 5% komponente аgensa za stаbilizаciju po težini formulаcije, od 10% do 35% komponente rаstvаrаčа po težini formulаcije, i od 0,5% do 1,5% (R)-3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirаzol-1-il] propаn-nitrila, ili njegove fаrmаceutski prihvаtljive soli, po težini formulаcije u odnosu na slobodnu bаzu; ili b) od 40% do 60% vode po težini formulаcije, od 5% do 10% komponente okluzivnog agensa po težini formulаcije, od 2% do 8% komponente agensa za učvršćivanje po težini pomenute formulаcije, od 7% do 12% komponente emolijensa po težini formulаcije, od 2% do 6% komponente emulgаtorа po težini formulаcije, od 0,1% do 2% аgensа zа stаbilizаciju po težini formulаcije, od 15% do 30% komponente rаstvаrаča po težini formulаcije, i od 0,5% do 1,5% (R)-3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirаzol-1-il] propаn-nitrila, ili njegove fаrmаceutski prihvаtljive soli, po težini formulаcije u odnosu nа slobodnu bаzu; ili c) od 45% do 55% vode po težini formulаcije, od 5% do 10% komponente okluzivnog agensa po težini formulаcije, od 3% do 6% komponente agensa za učvršćivanje po težini pomenute formulаcije, od 7% do 13% komponente emolijensa po težini formulаcije, od 3% do 5% komponente emulgаtora po težini formulаcije, od 0,3% do 0,5% komponente аgensa za stаbilizаciju po težini formulаcije, od 20% do 25% komponente rаstvаrаčа po težini formulаcije, i od 0,5% do 1,5% (R)-3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirаzol-1-il] propаnnitrila, ili njegove fаrmаceutski prihvаtljive soli, po težini formulаcije u odnosu na slobodnu bаzu; ili g) od 45% do 55% vode po težini formulаcije, od 5% do 10% komponente okluzivnog agensa po težini formulаcije, od 4% do 7% komponente agensa za učvršćivanje po težini pomenute formulаcije, od 7% do 13% komponente emolijensa po težini formulаcije, od 4% do 7% komponente emulgаtorа po težini formulаcije, od 0,3% do 0,5% komponente аgensa za stаbilizаciju po težini formulаcije, od 20% do 25% komponente rаstvаrаčа po težini formulаcije, i od 0,5% do 1,5% (R)-3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirаzol-1-il] propаn- nitrila, ili njegove fаrmаceutski prihvаtljive soli, po težini formulаcije u odnosu na slobodnu bаzu; ili e) od 45% do 55% vode po težini formulаcije, oko 7% komponente okluzivni agens po težini formulаcije, od 4,5% do 5% komponente agensa za učvršćivanje po težini pomenute formulаcije, oko 10% komponente emolijensa po težini formulаcije, od 4% do 4,5% komponente emulgаtorа po težini formulаcije, oko 0,4% komponente аgensa za stаbilizаciju po težini formulаcije, oko 22% komponente rаstvаrаčа po težini formulаcije, i od 0,5% do 1,5% (R)-3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirаzol-1-il]propаnnitrila, ili njegove fаrmаceutski prihvаtljive soli, po težini formulаcije u odnosu na slobodnu bazu.
26. Fаrmаceutskа formulаcijа premа zаhtevu 25, nаznаčena time što kombinovаnа količinа komponente ukrućivač i komponente emulgаtor iznosi nаjmаnje oko 8% po mаsi formulаcije.
27. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 25 do 26, nаznаčena time što: а) komponentа okluzivni аgens sаdrži petrolatum, komponentа ukrućivač sadrži jednu ili više supstаnci nezаvisno izаbrаnih od jednog ili više mаsnih аlkoholа, komponentа emolijens sаdrži jednu ili više supstаnci nezаvisno izabrаnih od minerаlnih uljа i trigliceridа, komponentа emulgаtor sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od gliceril mаsnih estara i sorbitаn mаsnih estara, komponentа аgens za stаbilizаciju sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od polisаhаridа, i komponentа rаstvаrаč sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od аlkilen glikolа i poliаlkilen glikolа; ili b) komponentа okluzivni аgens sаdrži beli petrolatum, komponentа ukrućivač sadrži jednu ili više supstаnci nezаvisno izаbrаnih od cetil аlkoholа i steаril аlkoholа, komponentа emolijens sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od lаkog minerаlnog ulja, trigliceridа srednjeg lаncа i dimetikona, komponentа emulgаtor sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od gliceril steаrаta i polisorbаta 20, komponentа аgens za stаbilizаciju sаdrži ksаntаn gumu, i komponentа rаstvаrаč sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od propilen glikolа i polietilen glikola.
28. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 1 do 27, koja dаlje sаdrži komponentu аntimikrobni konzervаns.
29. Fаrmаceutskа formulаcijа premа zаhtevu 28, nаznаčena time da: а) komponentа аntimikrobni konzervаns je prisutnа u količini od 0.05% do 3% po težini formulаcije; ili b) komponentа аntimikrobni konzervаns je prisutnа u količini od 0.1% do 1% po težini formulаcije.
30. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 28 do 29, u kojoj: а) komponentа аntimikrobni konzervans sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od аlkil pаrаbena i fenoksietаnola; ili b) komponentа аntimikrobni konzervans sаdrži jednu ili više supstаnci nezаvisno izаbrаnih od metil pаrаbena, propil pаrаbena, i fenoksietаnola.
31. Fаrmаceutskа formulаcijа premа bilo kojem od zаhtevа od 1 do 30: а) koja dаlje sаdrži komponentu helаcioni аgens; ili b) koja dаlje sаdrži komponentu helаcioni аgens gde komponentа helаcioni аgens sаdrži dinаtrijum-edetаt.
32. Fаrmаceutskа formulаcijа premа bilo kojem od pаtentnih zаhtevа od 1 do 31 zа upotrebu u lečenju poremećаjа kože.
33. Fаrmаceutskа formulаcijа zа upotrebu premа zаhtevu 32, nаznаčena time što: а) poremećаj kože je аtopični dermаtitis ili psorijаzа; ili b) poremećаj kože je psorijаzа; ili c) nаvedeni poremećаj kože je senzitizacija kože, iritаcija kože, osip nа koži, kontаktni dermаtitis ili kontаktna аlergijska senzitizacija; ili d) nаvedeni poremećаj kože je bulozni poremećаj kože; ili e) nаvedeni poremećаj kože je bulozni poremećаj kože, a pomenuti bulozni poremećаj kože je pemfigus vulgаris (PV) ili bulozni pemfigoid (BP).
34. Upotrebа fаrmаceutske formulаcije premа bilo kojem od pаtentnih zаhtevа od 1 do 33 zа dobijаnje lekа zа upotrebu u lečenju poremećаjа kože kod pаcijentа kome je to potrebno.
MEP-2016-92A 2010-05-21 2011-05-20 Topikalna formulacija za inhibiciju jak-a ME02445B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34713210P 2010-05-21 2010-05-21
EP11724104.2A EP2574168B9 (en) 2010-05-21 2011-05-20 Topical formulation for a jak inhibitor
PCT/US2011/037291 WO2011146808A2 (en) 2010-05-21 2011-05-20 Topical formulation for a jak inhibitor

Publications (1)

Publication Number Publication Date
ME02445B true ME02445B (me) 2016-09-20

Family

ID=44201091

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2016-92A ME02445B (me) 2010-05-21 2011-05-20 Topikalna formulacija za inhibiciju jak-a

Country Status (35)

Country Link
US (13) US20110288107A1 (me)
EP (2) EP3087972A1 (me)
JP (8) JP5849312B2 (me)
KR (5) KR102040479B1 (me)
CN (2) CN103002875B (me)
AR (2) AR084691A1 (me)
AU (7) AU2011255443B2 (me)
BR (1) BR112012029653B1 (me)
CA (1) CA2799928C (me)
CL (1) CL2012003229A1 (me)
CO (1) CO6640250A2 (me)
CR (1) CR20120605A (me)
CY (1) CY1117815T1 (me)
DK (1) DK2574168T3 (me)
EA (2) EA035981B1 (me)
EC (2) ECSP13012546A (me)
ES (1) ES2581834T3 (me)
HR (1) HRP20160841T1 (me)
HU (1) HUE029035T2 (me)
IL (1) IL223084A (me)
ME (1) ME02445B (me)
MX (1) MX338228B (me)
MY (2) MY178634A (me)
NZ (1) NZ603686A (me)
PE (1) PE20130216A1 (me)
PH (1) PH12012502296B1 (me)
PL (1) PL2574168T3 (me)
RS (1) RS54824B1 (me)
SG (3) SG185567A1 (me)
SI (1) SI2574168T1 (me)
SM (1) SMT201600172B (me)
TW (1) TWI499421B (me)
UA (1) UA111588C2 (me)
WO (1) WO2011146808A2 (me)
ZA (1) ZA202001999B (me)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101391900B1 (ko) 2005-12-13 2014-05-02 인사이트 코포레이션 야누스 키나아제 억제제로서의 헤테로아릴 치환된 피롤로［2,3-ｂ］피리딘 및 피롤로［2,3-ｂ］피리미딘
WO2008157208A2 (en) 2007-06-13 2008-12-24 Incyte Corporation Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
DK2432472T3 (da) 2009-05-22 2019-11-18 Incyte Holdings Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer
TW201100429A (en) 2009-05-22 2011-01-01 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011039637A2 (en) 2009-10-02 2011-04-07 Foamix Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
PH12015502575A1 (en) 2010-03-10 2017-04-24 Incyte Corp Piperidin-4-yl azetidine derivatives as jak1 inhibitors
EP3087972A1 (en) 2010-05-21 2016-11-02 Incyte Holdings Corporation Topical formulation for a jak inhibitor
CN103415515B (zh) 2010-11-19 2015-08-26 因塞特公司 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物
CA2818545C (en) 2010-11-19 2019-04-16 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
PL2675451T3 (pl) 2011-02-18 2016-05-31 Novartis Pharma Ag Terapia skojarzona z inhibitorem mTOR/JAK
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
WO2013023119A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
LT3196202T (lt) 2011-09-02 2019-07-10 Incyte Holdings Corporation Heterociklilaminai, kaip pi3k slopikliai
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
CA2888816A1 (en) 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
EP3949953A1 (en) 2012-11-15 2022-02-09 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
BR112015021458B1 (pt) 2013-03-06 2022-06-07 Incyte Holdings Corporation "processos e intermediários para preparar {1-{1-[3-flúor2-(trifluormetil)isonicotinoil] piperidin-4-il}-3-[4-(7hpirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrila, útil no tratamento de doenças relacionadas com a atividade de janus quinases
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
UA117830C2 (uk) 2013-05-17 2018-10-10 Інсайт Корпорейшн Похідні біпіразолу як інгібітори jak
WO2015021153A1 (en) 2013-08-07 2015-02-12 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
NZ763326A (en) 2014-04-08 2023-04-28 Incyte Holdings Corp Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
CR20160553A (es) 2014-04-30 2017-04-25 Incyte Corp Procesos para preparar un inhibidor de jak1 y nuevas formas de este
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
JP6770946B2 (ja) * 2014-07-25 2020-10-21 ノバルティス アーゲー ２−フルオロ−ｎ−メチル−４−［７−（キノリン−６−イルメチル）イミダゾ［１，２−ｂ］［１，２，４］トリアジン−２−イル］ベンズアミドの錠剤
CZ2014773A3 (cs) * 2014-11-10 2016-05-18 Zentiva, K.S. Soli (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu
CZ201629A3 (cs) * 2016-01-22 2017-08-02 Zentiva, K.S. Krystalické modifikace solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a způsoby jejich přípravy
EP3714887A4 (en) * 2017-11-20 2021-08-11 Jiangsu Hengrui Medicine Co. Ltd. PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION AND RELATED PREPARATION PROCESS
AU2018372180B2 (en) 2017-11-21 2023-08-17 Denali Therapeutics Inc. Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
CN112088003B (zh) 2017-12-20 2023-10-13 戴纳立制药公司 制备嘧啶基-4-氨基吡唑化合物的工艺
WO2019138291A2 (en) * 2018-01-09 2019-07-18 Dermavant Sciences GmbH Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof
DK3746429T3 (da) 2018-01-30 2022-05-02 Incyte Corp Fremgangsmåder til fremstilling af (1-(3-fluor-2-(trifluormethyl)isonicotinyl)piperidin-4-on)
BR122023022189A2 (pt) 2018-02-16 2024-02-20 Incyte Corporation Usos de inibidores da via de jak1 para o tratamento de distúrbios relacionados a citocinas
EP3775284A1 (en) 2018-03-30 2021-02-17 Incyte Corporation Biomarkers for inflammatory skin disease
CN112423759A (zh) 2018-03-30 2021-02-26 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
MX2020010815A (es) 2018-04-13 2020-12-11 Incyte Corp Biomarcadores para enfermedad de injerto contra hospedero.
PE20211208A1 (es) 2018-06-01 2021-07-05 Incyte Corp Regimen de dosificacion para el tratamiento de trastornos relacionados con pi3k
JP6830460B2 (ja) * 2018-07-05 2021-02-17 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
EA202191170A1 (ru) 2018-10-31 2021-07-27 Инсайт Корпорейшн Комбинированная терапия для лечения гематологических заболеваний
MA54551A (fr) 2018-12-20 2021-10-27 Incyte Corp Composés d'imidazopyridazine et d'imidazopyridine utilisés en tant qu'inhibiteurs de la kinase 2 de type récepteur de l'activine
WO2020252012A1 (en) 2019-06-10 2020-12-17 Incyte Corporation Topical treatment of vitiligo by a jak inhibitor
US11510923B2 (en) 2019-09-05 2022-11-29 Incyte Corporation Ruxolitinib formulation for reduction of itch in atopic dermatitis
US12360120B2 (en) 2019-10-10 2025-07-15 Incyte Corporation Biomarkers for graft-versus-host disease
JP2022551649A (ja) 2019-10-10 2022-12-12 インサイト・コーポレイション 移植片対宿主病のバイオマーカー
CN115038443A (zh) 2019-11-22 2022-09-09 因西特公司 包含alk2抑制剂和jak2抑制剂的组合疗法
IL298118B1 (en) 2020-06-02 2025-10-01 Incyte Corp Processes for preparing JAK1 inhibitor
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CA3189561A1 (en) * 2020-07-17 2022-01-20 Pfizer Inc. Stable pharmaceutical topical formulation containing immunosuppressant for treating dermatological conditions
AU2021329303A1 (en) 2020-08-18 2023-04-06 Incyte Corporation Process and intermediates for preparing a JAK inhibitor
MX2023002035A (es) 2020-08-18 2023-06-12 Incyte Corp Proceso e intermediarios para preparar un inhibidor de cinasa janus 1 (jak1).
JP2023542137A (ja) * 2020-09-16 2023-10-05 インサイト・コーポレイション 白斑の局所処置
JP2023544728A (ja) 2020-10-02 2023-10-25 インサイト・コーポレイション 扁平苔癬の治療のための局所ルキソリチニブ
PL4255442T3 (pl) 2020-12-04 2025-09-01 Incyte Corporation Inhibitor jak z analogiem witaminy d do leczenia chorób skóry
WO2022125670A1 (en) 2020-12-08 2022-06-16 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo
DK4333840T3 (da) 2021-05-03 2025-11-24 Incyte Corp Jak1-vejinhibitorer til behandling af prurigo nodularis
EP4333849A1 (en) 2021-05-03 2024-03-13 Incyte Corporation Ruxolitinib for the treatment of prurigo nodularis
CN113264936B (zh) * 2021-05-25 2022-08-09 常州制药厂有限公司 一种jak抑制剂关键中间体及其制备方法
US12071439B2 (en) 2021-07-12 2024-08-27 Incyte Corporation Process and intermediates for preparing a JAK inhibitor
CN115702936A (zh) * 2021-08-13 2023-02-17 杭州中美华东制药有限公司 一种芦可替尼组合物及其用途
CA3229388A1 (en) * 2021-08-19 2023-02-23 Zhuhai United Laboratories Co., Ltd. Local topical preparation containing jak inhibitor, salts or crystal forms thereof, and preparation method and use thereof
CN115869321A (zh) 2021-09-28 2023-03-31 杭州中美华东制药有限公司 一种芦可替尼组合物及其制备方法
CN114870016B (zh) * 2022-04-21 2023-05-26 上海博悦生物科技有限公司 一种jak抑制剂的微乳泡沫剂及其应用
CA3259499A1 (en) 2022-06-14 2023-12-21 Incyte Corp SOLID FORMS OF A JAK INHIBITOR AND THEIR PREPARATION METHOD
CN119157880A (zh) * 2023-06-20 2024-12-20 中国医学科学院药物研究所 一种6-氨基-1H-吡唑并[3,4-d]嘧啶类JAK3激酶抑制剂在治疗特应性皮炎中的应用
WO2025096373A1 (en) 2023-11-02 2025-05-08 Incyte Corporation Ruxolitinib for use in the treatment of prurigo nodularis
WO2025117642A1 (en) 2023-12-01 2025-06-05 Incyte Corporation Ruxolitinib for treating hidradenitis suppurativa (hs)
CN119424386B (zh) * 2024-10-12 2025-07-25 深圳市泰力生物医药有限公司 含有芦可替尼的外用速溶膜及其制备方法和应用

Family Cites Families (281)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2985589A (en) 1957-05-22 1961-05-23 Universal Oil Prod Co Continuous sorption process employing fixed bed of sorbent and moving inlets and outlets
US3832460A (en) 1971-03-19 1974-08-27 C Kosti Anesthetic-vasoconstrictor-antihistamine composition for the treatment of hypertrophied oral tissue
US4140755A (en) 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
DE3036390A1 (de) 1980-09-26 1982-05-13 Troponwerke GmbH & Co KG, 5000 Köln Neue pyrrolo-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von biologischen wirkstoffen
DE3220113A1 (de) 1982-05-28 1983-12-01 Basf Ag, 6700 Ludwigshafen Difluormethoxiphenylthiophosphorsaeureester
US4402832A (en) 1982-08-12 1983-09-06 Uop Inc. High efficiency continuous separation process
US4548990A (en) 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US4498991A (en) 1984-06-18 1985-02-12 Uop Inc. Serial flow continuous separation process
NL8403224A (nl) 1984-10-24 1986-05-16 Oce Andeno Bv Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.
CA1306260C (en) 1985-10-18 1992-08-11 Shionogi & Co., Ltd. Condensed imidazopyridine derivatives
US5702688A (en) * 1986-12-23 1997-12-30 Tristrata Technology, Inc. Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use
ATE139232T1 (de) 1989-10-11 1996-06-15 Teijin Ltd Bizyklische pyrimidinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung
IT1258781B (it) 1992-01-16 1996-02-29 Zambon Spa Composizione farmaceutica oftalmica contenente n-acetilcisteina e polivinilalcol
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
AU671491B2 (en) 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
JPH0710876A (ja) 1993-06-24 1995-01-13 Teijin Ltd ４位に環状アミノ基を有するピロロ［２，３―ｄ］ピリミジン
EP0727217A3 (en) 1995-02-10 1997-01-15 Suntory Ltd Pharmaceutical and cosmetic compositions containing God-type ellagitannin as an active ingredient
IL117580A0 (en) 1995-03-29 1996-07-23 Merck & Co Inc Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
US5856326A (en) 1995-03-29 1999-01-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CN1105113C (zh) 1995-07-05 2003-04-09 纳幕尔杜邦公司 杀真菌嘧啶酮
US5630943A (en) 1995-11-30 1997-05-20 Merck Patent Gesellschaft Mit Beschrankter Haftung Discontinuous countercurrent chromatographic process and apparatus
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
CA2250232A1 (en) 1996-04-03 1997-10-09 Allen I. Oliff A method of treating cancer
WO1997038664A2 (en) 1996-04-18 1997-10-23 Merck & Co., Inc. A method of treating cancer
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
JP2000508335A (ja) 1996-05-30 2000-07-04 メルク エンド カンパニー インコーポレーテッド 癌の治療方法
US6624138B1 (en) 2001-09-27 2003-09-23 Gp Medical Drug-loaded biological material chemically treated with genipin
JP2001524079A (ja) 1997-04-07 2001-11-27 メルク エンド カンパニー インコーポレーテッド ガンの治療方法
US6060038A (en) 1997-05-15 2000-05-09 Merck & Co., Inc. Radiolabeled farnesyl-protein transferase inhibitors
US6063284A (en) 1997-05-15 2000-05-16 Em Industries, Inc. Single column closed-loop recycling with periodic intra-profile injection
CA2295620A1 (en) 1997-08-11 1999-02-18 Boehringer Ingelheim Pharmaceuticals, Inc. 5,6-heteroaryl-dipyrido¬2,3-b:3',2'-f|azepines and their use in the prevention or treatment of hiv infection
US6075056A (en) * 1997-10-03 2000-06-13 Penederm, Inc. Antifungal/steroid topical compositions
US6025366A (en) 1998-04-02 2000-02-15 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
IL139811A0 (en) 1998-06-04 2002-02-10 Abbott Lab Cell adhesion-inhibiting antinflammatory compounds
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
EP1107964B8 (en) 1998-08-11 2010-04-07 Novartis AG Isoquinoline derivatives with angiogenesis inhibiting activity
JP2000119271A (ja) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
TR200100708T2 (tr) 1998-09-10 2001-07-23 Nycomed Danmark A/S İlaç maddelerine mahsus çabuk salımlı farmasötik bileşimler.
FR2785196B1 (fr) 1998-10-29 2000-12-15 Inst Francais Du Petrole Procede et dispositif de separation avec des zones chromatographiques a longueur variable
US6375839B1 (en) 1998-10-29 2002-04-23 Institut Francais Du Petrole Process and device for separation with variable-length chromatographic zones
US6413419B1 (en) 1998-10-29 2002-07-02 Institut Francais Du Petrole Process and device for separation with variable-length chromatographic
US6333384B1 (en) 1998-11-02 2001-12-25 Gil Technologies Vinyl-terminated polybutadiene and butadiene-styrene copolymers containing urethane and/or ester residues, and the electrical laminates obtained therefrom
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
JP2002538121A (ja) 1999-03-03 2002-11-12 メルク エンド カムパニー インコーポレーテッド プレニルタンパク質トランスフェラーゼの阻害剤
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
WO2000063168A1 (en) 1999-04-16 2000-10-26 Coelacanth Chemical Corporation Synthesis of azetidine derivatives
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
DE60013464T2 (de) 1999-10-13 2005-09-15 Banyu Pharmaceutical Co., Ltd. Substituierte imidazolin-derivate
CZ303875B6 (cs) 1999-12-10 2013-06-05 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidinová sloucenina a farmaceutická kompozice s jejím obsahem
IL150388A0 (en) 1999-12-24 2002-12-01 Aventis Pharma Ltd Azaindoles
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
ES2206363T3 (es) 2000-04-07 2004-05-16 Laboratoire Medidom S.A. Formulaciones oftalmicas a base de ciclosporina, de acido hialuronico y de polisorbato.
WO2001081345A1 (en) 2000-04-20 2001-11-01 Mitsubishi Pharma Corporation Aromatic amide compounds
KR100785363B1 (ko) 2000-04-25 2007-12-18 이코스 코포레이션 인간 포스파티딜-이노시톨 3-키나제 델타의 억제제
EP1294752A2 (en) 2000-06-16 2003-03-26 Curis, Inc. Angiogenesis-modulating compositions and uses
US7498304B2 (en) 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
US6335342B1 (en) 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
ATE465756T1 (de) 2000-06-23 2010-05-15 Mitsubishi Tanabe Pharma Corp Antitumoreffekt-verstärker
EA006153B1 (ru) 2000-06-26 2005-10-27 Пфайзер Продактс Инк. СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИММУНОДЕПРЕССАНТОВ
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
ES2307667T3 (es) 2000-12-05 2008-12-01 Vertex Pharmaceuticals Incorporated Inhibidires de quinasas terminales c-jun(jnk) y otras proteinas quinasas.
GB0100622D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds V111
WO2002055496A1 (en) 2001-01-15 2002-07-18 Glaxo Group Limited Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
WO2002060492A1 (en) 2001-01-30 2002-08-08 Cytopia Pty Ltd Methods of inhibiting kinases
AU2002308748A1 (en) 2001-05-16 2002-11-25 Vertex Pharmaceuticals Incorporated Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
CA2455181C (en) 2001-08-01 2010-04-06 Merck & Co., Inc. Benzimidazo[4,5-f]isoquinolinone derivatives
WO2003024967A2 (en) 2001-09-19 2003-03-27 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
US6429231B1 (en) 2001-09-24 2002-08-06 Bradley Pharmaceuticals, Inc. Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use
EP1441737B1 (en) 2001-10-30 2006-08-09 Novartis AG Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
JP2003155285A (ja) 2001-11-19 2003-05-27 Toray Ind Inc 環状含窒素誘導体
US6949668B2 (en) 2001-11-30 2005-09-27 Teijin Limited Process for producing 5-(3-cyanophenyl)-3-formylbenzoic acid compound
GT200200234A (es) 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
WO2003091246A1 (en) 2002-04-26 2003-11-06 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
EP1503757B1 (en) 2002-05-02 2007-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
MXPA04011004A (es) 2002-05-07 2005-01-25 Control Delivery Sys Inc Procesos para formar un dispositivo de administracion de farmaco.
US7122550B2 (en) 2002-05-23 2006-10-17 Cytopia Pty Ltd Protein kinase inhibitors
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
CN1630668A (zh) 2002-06-26 2005-06-22 出光兴产株式会社 氢化共聚物及其制备方法以及包含氢化共聚物的热熔粘合剂组合物
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
WO2004007472A1 (ja) 2002-07-10 2004-01-22 Ono Pharmaceutical Co., Ltd. Ｃｃｒ４アンタゴニストおよびその医薬用途
CA2497977A1 (en) 2002-09-20 2004-04-01 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
US20040204404A1 (en) 2002-09-30 2004-10-14 Robert Zelle Human N-type calcium channel blockers
US7259161B2 (en) 2002-11-04 2007-08-21 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of JAK and other protein kinases
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
US20040099204A1 (en) 2002-11-25 2004-05-27 Nestor John J. Sheet, page, line, position marker
CA2507392A1 (en) 2002-11-26 2004-06-10 Pfizer Products Inc. Method of treatment of transplant rejection
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
TWI335819B (en) 2002-12-24 2011-01-11 Alcon Inc Use of oculosurface selective glucocorticoid in the treatment of dry eye
US7135493B2 (en) 2003-01-13 2006-11-14 Astellas Pharma Inc. HDAC inhibitor
US7167750B2 (en) 2003-02-03 2007-01-23 Enteromedics, Inc. Obesity treatment with electrically induced vagal down regulation
US7407962B2 (en) 2003-02-07 2008-08-05 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors or protein kinases
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP2006522124A (ja) 2003-04-03 2006-09-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用な組成物
SE0301372D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
SE0301373D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
FR2857454B1 (fr) 2003-07-08 2006-08-11 Aventis Pasteur Dosage des acides techoiques des bacteries gram+
US20050043346A1 (en) 2003-08-08 2005-02-24 Pharmacia Italia S.P.A. Pyridylpyrrole derivatives active as kinase inhibitors
JP5010917B2 (ja) 2003-08-29 2012-08-29 エグゼリクシス， インコーポレイテッド ｃ−Ｋｉｔ調節因子および使用方法
EP1678147B1 (en) 2003-09-15 2012-08-08 Lead Discovery Center GmbH Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
SI1679074T1 (sl) 2003-10-24 2011-04-29 Santen Pharmaceutical Co Ltd Terapevtsko sredstvo za keratokonjuktivno motnjo
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
WO2005051393A1 (en) 2003-11-25 2005-06-09 Pfizer Products Inc. Method of treatment of atherosclerosis
MXPA06007002A (es) 2003-12-17 2006-08-31 Pfizer Prod Inc Compuestos de pirrolo[2,3-d]pirimidina para tratar rechazo de transplantes.
DK1696920T3 (en) 2003-12-19 2015-01-19 Plexxikon Inc RELATIONS AND PROCEDURES FOR THE DEVELOPMENT OF LAW MODULATORS
ATE406356T1 (de) 2003-12-19 2008-09-15 Schering Corp Thiadiazole als cxc- und cc- chemokinrezeptorliganden
HRP20100675T1 (hr) 2003-12-23 2011-01-31 Astex Therapeutics Limited Derivati pirazola kao modulatori protein kinaze
US20050187389A1 (en) 2004-01-13 2005-08-25 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
EP1744751A4 (en) 2004-03-18 2010-03-10 Brigham & Womens Hospital METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
WO2005095400A1 (en) 2004-03-30 2005-10-13 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of jak and other protein kinases
JP5213229B2 (ja) 2004-04-23 2013-06-19 エグゼリクシス， インコーポレイテッド キナーゼ調節因子および使用方法
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
US7558717B2 (en) 2004-04-28 2009-07-07 Vertex Pharmaceuticals Incorporated Crystal structure of human JAK3 kinase domain complex and binding pockets thereof
EP1755680A1 (en) 2004-05-03 2007-02-28 Novartis AG Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor
US20060074102A1 (en) 2004-05-14 2006-04-06 Kevin Cusack Kinase inhibitors as therapeutic agents
PE20060426A1 (es) 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
RU2401265C2 (ru) 2004-06-10 2010-10-10 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназы
WO2006001463A1 (ja) 2004-06-23 2006-01-05 Ono Pharmaceutical Co., Ltd. Ｓ１ｐ受容体結合能を有する化合物およびその用途
WO2006004984A1 (en) 2004-06-30 2006-01-12 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of protein kinases
US7138423B2 (en) 2004-07-20 2006-11-21 Bristol-Myers Squibb Company Arylpyrrolidine derivatives as NK-1 /SSRI antagonists
FR2873691B1 (fr) 2004-07-29 2006-10-06 Sanofi Synthelabo Derives d'amino-piperidine, leur preparation et leur application en therapeutique
WO2006013114A1 (en) 2004-08-06 2006-02-09 Develogen Aktiengesellschaft Use of a timp-2 secreted protein product for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
CN101006186A (zh) 2004-08-23 2007-07-25 财团法人牧岩生命工学研究所 用于检测sars冠状病毒的引物和探针，包括该引物和/或探针的试剂盒及其检测方法
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CN101899049A (zh) 2004-10-13 2010-12-01 霍夫曼-拉罗奇有限公司 二取代吡唑并苯并二氮杂*类
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
US7528138B2 (en) 2004-11-04 2009-05-05 Vertex Pharmaceuticals Incorporated Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
KR20070085433A (ko) 2004-11-24 2007-08-27 노파르티스 아게 Ｊａｋ 저해제들과 ｂｃｒ-ａｂｌ, ｆｌｔ-3, ｆａｋ 또는ｒａｆ 키나제 저해제들 중 하나 이상의 조합물
US7517870B2 (en) 2004-12-03 2009-04-14 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
US20060128803A1 (en) 2004-12-14 2006-06-15 Alcon, Inc. Method of treating dry eye disorders using 13(S)-HODE and its analogs
WO2006067445A2 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Csf-1r kinase inhibitors
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
EP1844037A1 (en) 2005-01-20 2007-10-17 Pfizer Limited Chemical compounds
JP5227032B2 (ja) 2005-02-03 2013-07-03 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼの阻害剤として有用なピロロピリミジン
WO2007044050A2 (en) 2005-02-04 2007-04-19 Bristol-Myers Squibb Company 1h-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
BRPI0608513A2 (pt) 2005-03-15 2010-01-05 Irm Llc compostos e composições como inibidores da proteìna quinase
AU2006232105A1 (en) 2005-04-05 2006-10-12 Pharmacopeia, Inc. Purine and imidazopyridine derivatives for immunosuppression
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
RU2435769C2 (ru) 2005-05-20 2011-12-10 Вертекс Фармасьютикалз Инкорпорейтед Пирролопиридины, полезные в качестве ингибиторов протеинкиназы
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
RU2485106C2 (ru) 2005-06-08 2013-06-20 Райджел Фамэсьютикэлз, Инк. Соединения, проявляющие активность в отношении jak-киназы (варианты), способ лечения заболеваний, опосредованных jak-киназой, способ ингибирования активности jak-киназы (варианты), фармацевтическая композиция на основе указанных соединений
WO2006136823A1 (en) 2005-06-21 2006-12-28 Astex Therapeutics Limited Heterocyclic containing amines as kinase b inhibitors
WO2007002433A1 (en) 2005-06-22 2007-01-04 Plexxikon, Inc. Pyrrolo [2, 3-b] pyridine derivatives as protein kinase inhibitors
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
FR2889662B1 (fr) * 2005-08-11 2011-01-14 Galderma Res & Dev Emulsion de type huile-dans-eau pour application topique en dermatologie
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
US20070149506A1 (en) 2005-09-22 2007-06-28 Arvanitis Argyrios G Azepine inhibitors of Janus kinases
NZ567133A (en) 2005-09-30 2011-07-29 Vertex Pharma Deazapurines useful as inhibitors of janus kinases
WO2007044894A2 (en) 2005-10-11 2007-04-19 Chembridge Research Laboratories, Inc. Cell-free protein expression systems and methods of use thereof
KR101315574B1 (ko) 2005-10-14 2013-10-08 스미또모 가가꾸 가부시끼가이샤 히드라지드 화합물 및 이의 살충 용도
WO2007049041A1 (en) 2005-10-28 2007-05-03 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
MY167260A (en) 2005-11-01 2018-08-14 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
WO2007062459A1 (en) 2005-11-29 2007-06-07 Cytopia Research Pty Ltd Selective kinase inhibitors based on pyridine scaffold
US20130137681A1 (en) 2005-12-13 2013-05-30 Incyte Corporation HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
KR101391900B1 (ko) 2005-12-13 2014-05-02 인사이트 코포레이션 야누스 키나아제 억제제로서의 헤테로아릴 치환된 피롤로［2,3-ｂ］피리딘 및 피롤로［2,3-ｂ］피리미딘
WO2007076423A2 (en) 2005-12-22 2007-07-05 Smithkline Beecham Corporation INHIBITORS OF Akt ACTIVITY
SI1962830T1 (sl) 2005-12-23 2013-07-31 Glaxosmithkline Llc Azaindolni inhibitorji kinaz Aurora
NZ601687A (en) 2006-01-17 2014-03-28 Vertex Pharma Azaindoles useful as inhibitors of janus kinases
EP1979353A2 (en) 2006-01-19 2008-10-15 OSI Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
JP2009525350A (ja) 2006-02-01 2009-07-09 スミスクライン ビーチャム コーポレーション Ｒａｆキナーゼ阻害薬として有用なピロロ［２，３，ｂ］ピリジン誘導体
US7745477B2 (en) 2006-02-07 2010-06-29 Hoffman-La Roche Inc. Heteroaryl and benzyl amide compounds
US8003642B2 (en) 2006-03-10 2011-08-23 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
FR2898498B1 (fr) * 2006-03-15 2008-11-28 Galderma Sa Nouvelles compositions topiques sous forme d'emulsion h/e comprenant un glycol pro-penetrant
AU2007236707C1 (en) 2006-04-03 2012-05-24 Astellas Pharma Inc. Hetero compound
US8741912B2 (en) 2006-04-05 2014-06-03 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of Janus kinases
US20090124636A1 (en) 2006-04-12 2009-05-14 Pfizer Inc. Chemical compounds
WO2007129195A2 (en) 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
US20080051427A1 (en) 2006-05-18 2008-02-28 Fritz Schuckler Pharmaceutical Compositions and Methods of Using Same
US7691811B2 (en) 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
CA2658764A1 (en) 2006-07-20 2008-01-24 Mehmet Kahraman Benzothiophene inhibitors of rho kinase
US8715700B2 (en) * 2006-07-21 2014-05-06 Dow Pharmaceutical Sciences, Inc. Alpha hydroxy acid sustained release formulation
WO2008013622A2 (en) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
US8492378B2 (en) 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
US8318723B2 (en) 2006-08-16 2012-11-27 Boehringer Ingelheim International Gmbh Pyrazine compounds, their use and methods of preparation
AU2007293653B2 (en) 2006-09-08 2011-02-17 Novartis Ag N-biaryl (hetero) arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions
WO2008035376A2 (en) 2006-09-19 2008-03-27 Council Of Scientific & Industrial Research A novel bio-erodible insert for ophthalmic applications and a process for the preparation thereof
AR063142A1 (es) 2006-10-04 2008-12-30 Pharmacopeia Inc Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen.
US7915268B2 (en) 2006-10-04 2011-03-29 Wyeth Llc 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
US20120225057A1 (en) 2006-10-11 2012-09-06 Deciphera Pharmaceuticals, Llc Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
CA2667487C (en) 2006-11-06 2017-04-04 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
US20080119496A1 (en) 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
GEP20125658B (en) 2006-11-22 2012-10-10 Incyte Corp Imidazotriazines and imidazo pyrimidines as kinase inhibitors
WO2008067119A2 (en) 2006-11-27 2008-06-05 Smithkline Beecham Corporation Novel compounds
AU2007334436A1 (en) 2006-12-15 2008-06-26 Abbott Laboratories Novel oxadiazole compounds
AU2007338792B2 (en) 2006-12-20 2012-05-31 Amgen Inc. Substituted heterocycles and methods of use
MX2009006543A (es) 2006-12-20 2009-06-26 Amgen Inc Compuestos heterociclicos y su uso en el tratamiento de la inflamacion, angiogenesis y cancer.
AU2007338210B2 (en) 2006-12-22 2013-01-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Gel useful for the delivery of ophthalmic drugs
EP2121692B1 (en) 2006-12-22 2013-04-10 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
WO2008082840A1 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
WO2008082839A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
KR20080062876A (ko) 2006-12-29 2008-07-03 주식회사 대웅제약 신규한 항진균성 트리아졸 유도체
EA019951B1 (ru) 2007-03-01 2014-07-30 Новартис Аг Ингибиторы киназы pim и способы их применения
UA101611C2 (ru) 2007-04-03 2013-04-25 Аррей Байофарма Инк. СОЕДИНЕНИЯ ИМИДАЗО[1,2-а]ПИРИДИНА КАК ИНГИБИТОРЫ ТИРОЗИНКИНАЗЫ РЕЦЕПТОРОВ
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
WO2008145681A2 (en) 2007-05-31 2008-12-04 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
GB0710528D0 (en) 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
WO2008157208A2 (en) 2007-06-13 2008-12-24 Incyte Corporation Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
EP2175858B1 (en) 2007-07-11 2014-09-10 Pfizer Inc. Pharmaceutical compositions and methods of treating dry eye disorders
KR20100038119A (ko) 2007-08-01 2010-04-12 화이자 인코포레이티드 피라졸 화합물 및 ｒａｆ 억제제로서 이의 용도
WO2009049028A1 (en) 2007-10-09 2009-04-16 Targegen Inc. Pyrrolopyrimidine compounds and their use as janus kinase modulators
WO2009064486A2 (en) 2007-11-15 2009-05-22 Musc Foundation For Research Development Inhibitors of pim protein kinases, compositions, and methods for treating cancer
CN101910152B (zh) 2007-11-16 2014-08-06 因塞特公司 作为janus激酶抑制剂的4-吡唑基-n-芳基嘧啶-2-胺和4-吡唑基-n-杂芳基嘧啶-2-胺
GB0723815D0 (en) 2007-12-05 2008-01-16 Glaxo Group Ltd Compounds
TR201815961T4 (tr) 2008-01-18 2018-11-21 Inst Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Yeni sitostatik 7-deazapürin nükleozidleri.
MY158994A (en) 2008-02-04 2016-11-30 Mercury Therapeutics Inc Ampk modulators
AR070531A1 (es) 2008-03-03 2010-04-14 Novartis Ag Inhibidores de cinasa pim y metodos para su uso
MX2010010012A (es) 2008-03-11 2010-10-20 Incyte Corp Derivados de azetidina y ciclobutano como inhibidores de jak.
CN102015686B (zh) 2008-03-21 2014-07-02 诺华股份有限公司 杂环化合物及其用途
KR20160130519A (ko) * 2008-06-26 2016-11-11 안테리오스, 인코퍼레이티드 경피 운반
UY31952A (es) 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
FR2933409B1 (fr) 2008-07-03 2010-08-27 Centre Nat Rech Scient NOUVEAUX PYRROLO °2,3-a! CARBAZOLES ET LEUR UTILISATION COMME INHIBITEURS DES KINASES PIM
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物
US8557809B2 (en) 2008-08-19 2013-10-15 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
PT2384326E (pt) 2008-08-20 2014-06-09 Zoetis Llc Compostos de pirrolo[2,3-d]pirimidina
MX2011002367A (es) 2008-09-02 2011-04-04 Novartis Ag Inhibidores de cinasa biciclicos.
US8759338B2 (en) 2008-09-02 2014-06-24 Novartis Ag Heterocyclic kinase inhibitors
BRPI0918268B1 (pt) 2008-09-02 2021-08-03 Novartis Ag Derivados de picolinamida, seu uso, e composição farmacêutica
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
WO2010043052A1 (en) 2008-10-17 2010-04-22 Merck Frosst Canada Ltd. Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
DK2432472T3 (da) 2009-05-22 2019-11-18 Incyte Holdings Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer
TW201100429A (en) 2009-05-22 2011-01-01 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
UA110324C2 (en) 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
CN101958119B (zh) 2009-07-16 2012-02-29 中兴通讯股份有限公司 一种改进的离散余弦变换域音频丢帧补偿器和补偿方法
WO2011066371A2 (en) 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antibodies to il-6 and use thereof
EP2470534A4 (en) 2009-08-24 2013-02-27 Merck Sharp & Dohme JAK INHIBITION FOR BLOCKING TOXICITY ASSOCIATED WITH RNA INTERFERENCE
TW201111385A (en) 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2475659B1 (en) 2009-09-08 2015-10-28 F.Hoffmann-La Roche Ag 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
EP2305660A1 (en) 2009-09-25 2011-04-06 Almirall, S.A. New thiadiazole derivatives
ES2435491T3 (es) 2009-10-09 2013-12-19 Incyte Corporation Derivados de hidroxilo, ceto y glucurónido de 3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo
AU2010309882B2 (en) 2009-10-20 2016-01-28 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors
EP2332917B1 (en) 2009-11-11 2012-08-01 Sygnis Bioscience GmbH & Co. KG Compounds for PIM kinase inhibition and for treating malignancy
WO2011069141A2 (en) 2009-12-04 2011-06-09 Board Of Regents, The University Of Texas System Interferon therapies in combination with blockade of stat3 activation
KR20140015162A (ko) 2010-01-12 2014-02-06 에프. 호프만-라 로슈 아게 트라이사이클릭 헤테로사이클릭 화합물, 조성물 및 이의 사용 방법
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
JP5858434B2 (ja) 2010-02-18 2016-02-10 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｎｕｓキナーゼ阻害薬としてのシクロブタンおよびメチルシクロブタン誘導体
PH12015502575A1 (en) 2010-03-10 2017-04-24 Incyte Corp Piperidin-4-yl azetidine derivatives as jak1 inhibitors
NZ603446A (en) 2010-04-14 2014-05-30 Array Biopharma Inc 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases
EP2390252A1 (en) 2010-05-19 2011-11-30 Almirall, S.A. New pyrazole derivatives
EP3087972A1 (en) 2010-05-21 2016-11-02 Incyte Holdings Corporation Topical formulation for a jak inhibitor
US8637529B2 (en) 2010-06-11 2014-01-28 AbbYie Inc. Pyrazolo[3,4-d]pyrimidine compounds
US9351943B2 (en) 2010-07-01 2016-05-31 Matthew T. McLeay Anti-fibroblastic fluorochemical emulsion therapies
EP2621489A1 (en) 2010-09-30 2013-08-07 Portola Pharmaceuticals, Inc. Combinations of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine
CA2818545C (en) 2010-11-19 2019-04-16 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CN103415515B (zh) 2010-11-19 2015-08-26 因塞特公司 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物
US20140073643A1 (en) 2010-12-03 2014-03-13 Ym Biosciences Australia Pty Ltd Treatment of jak2-mediated conditions
PL2675451T3 (pl) 2011-02-18 2016-05-31 Novartis Pharma Ag Terapia skojarzona z inhibitorem mTOR/JAK
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
WO2013023119A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
US10155987B2 (en) 2012-06-12 2018-12-18 Dana-Farber Cancer Institute, Inc. Methods of predicting resistance to JAK inhibitor therapy
EP2890691B1 (en) 2012-08-31 2018-04-25 Principia Biopharma Inc. Benzimidazole derivatives as itk inhibitors
CA2888816A1 (en) 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
EP3949953A1 (en) 2012-11-15 2022-02-09 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
BR112015021458B1 (pt) 2013-03-06 2022-06-07 Incyte Holdings Corporation "processos e intermediários para preparar {1-{1-[3-flúor2-(trifluormetil)isonicotinoil] piperidin-4-il}-3-[4-(7hpirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrila, útil no tratamento de doenças relacionadas com a atividade de janus quinases
UA117830C2 (uk) 2013-05-17 2018-10-10 Інсайт Корпорейшн Похідні біпіразолу як інгібітори jak
WO2015021153A1 (en) 2013-08-07 2015-02-12 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
TW201529074A (zh) 2013-08-20 2015-08-01 Incyte Corp 在ｃ-反應蛋白含量較高之實體腫瘤患者中的存活益處
SI3110409T1 (sl) 2014-02-28 2018-11-30 Incyte Corporation Inhibitorji JAK1 za zdravljenje mielodisplastičnih sindromov
NZ763326A (en) 2014-04-08 2023-04-28 Incyte Holdings Corp Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
CR20160553A (es) 2014-04-30 2017-04-25 Incyte Corp Procesos para preparar un inhibidor de jak1 y nuevas formas de este
EP3148545B1 (en) 2014-05-28 2023-03-15 Onco Tracker, Inc. Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1

Also Published As

Publication number Publication date
JP2021193140A (ja) 2021-12-23
HUE029035T2 (en) 2017-01-30
AU2011255443A1 (en) 2012-12-06
CR20120605A (es) 2013-03-11
US10869870B2 (en) 2020-12-22
UA111588C2 (uk) 2016-05-25
JP2020079281A (ja) 2020-05-28
US11571425B2 (en) 2023-02-07
AU2018201889B2 (en) 2020-03-05
RS54824B1 (sr) 2016-10-31
AU2022204807B2 (en) 2024-08-15
DK2574168T3 (en) 2016-05-09
CO6640250A2 (es) 2013-03-22
KR20220104166A (ko) 2022-07-26
JP6479877B2 (ja) 2019-03-06
KR102040479B1 (ko) 2019-11-06
US11219624B2 (en) 2022-01-11
CN105853356A (zh) 2016-08-17
AU2016204689A1 (en) 2016-07-21
BR112012029653B1 (pt) 2021-01-12
US20220370455A1 (en) 2022-11-24
JP6952143B2 (ja) 2021-10-20
KR20180101617A (ko) 2018-09-12
SMT201600172B (it) 2016-08-31
PL2574168T3 (pl) 2016-10-31
PE20130216A1 (es) 2013-02-27
AR124134A2 (es) 2023-02-15
JP7547435B2 (ja) 2024-09-09
KR20130109012A (ko) 2013-10-07
US11590136B2 (en) 2023-02-28
SG185567A1 (en) 2012-12-28
JP5849312B2 (ja) 2016-01-27
KR20210118207A (ko) 2021-09-29
IL223084A (en) 2017-03-30
WO2011146808A2 (en) 2011-11-24
EA202091303A3 (ru) 2021-05-31
ECSP13012546A (es) 2013-06-28
CL2012003229A1 (es) 2013-01-25
SI2574168T1 (sl) 2016-07-29
JP2023002758A (ja) 2023-01-10
MY178634A (en) 2020-10-19
KR102402137B1 (ko) 2022-05-30
EP2574168B1 (en) 2016-04-20
EP2574168A2 (en) 2013-04-03
US20220211712A1 (en) 2022-07-07
TW201201809A (en) 2012-01-16
AU2014202896A1 (en) 2014-06-19
JP6657441B2 (ja) 2020-03-04
KR102635013B1 (ko) 2024-02-13
US10758543B2 (en) 2020-09-01
HRP20160841T1 (hr) 2016-09-23
EA202091303A2 (ru) 2021-03-31
MY161078A (en) 2017-04-14
US20200046707A1 (en) 2020-02-13
US20220211707A1 (en) 2022-07-07
PH12012502296A1 (en) 2013-02-11
EP2574168B9 (en) 2016-10-05
CY1117815T1 (el) 2017-05-17
IL223084A0 (en) 2013-02-03
US20150250790A1 (en) 2015-09-10
AU2024264568A1 (en) 2024-11-28
AU2022204807A1 (en) 2022-07-28
US20110288107A1 (en) 2011-11-24
WO2011146808A3 (en) 2012-06-07
AU2018201889A1 (en) 2018-04-12
CA2799928C (en) 2020-03-31
US20220378792A1 (en) 2022-12-01
AR084691A1 (es) 2013-06-05
US12226419B2 (en) 2025-02-18
CN103002875B (zh) 2016-05-04
KR20190125531A (ko) 2019-11-06
KR101921466B1 (ko) 2018-11-26
ZA202001999B (en) 2022-03-30
EP3087972A1 (en) 2016-11-02
ECSP24034690A (es) 2024-06-28
AU2020201151A1 (en) 2020-03-05
HK1182313A1 (zh) 2013-11-29
JP2016053069A (ja) 2016-04-14
JP7167280B2 (ja) 2022-11-08
PH12012502296B1 (en) 2017-10-06
CN105853356B (zh) 2019-07-16
EA201291310A1 (ru) 2013-06-28
CA2799928A1 (en) 2011-11-24
US20250255872A1 (en) 2025-08-14
MX2012013400A (es) 2013-02-26
TWI499421B (zh) 2015-09-11
CN103002875A (zh) 2013-03-27
EA035981B1 (ru) 2020-09-09
JP2019081783A (ja) 2019-05-30
JP2013529214A (ja) 2013-07-18
ES2581834T3 (es) 2016-09-07
AU2020201151B2 (en) 2022-04-07
US20210000832A1 (en) 2021-01-07
JP2024164235A (ja) 2024-11-26
US20250345337A1 (en) 2025-11-13
US20200368240A1 (en) 2020-11-26
US20240245687A1 (en) 2024-07-25
AU2011255443B2 (en) 2014-07-03
US20230277541A1 (en) 2023-09-07
SG10201503983QA (en) 2015-06-29
SG10201910912TA (en) 2020-01-30
KR102303885B1 (ko) 2021-09-24
MX338228B (es) 2016-04-08
NZ603686A (en) 2014-11-28
JP2017149739A (ja) 2017-08-31
BR112012029653A2 (pt) 2016-08-02

Similar Documents

Publication Publication Date Title
ME02445B (me) Topikalna formulacija za inhibiciju jak-a
ES2370907T3 (es) Composición en forma de pulverizador que comprende una combinación de un corticoide y un derivado de vitamina d en una fase oleosa.
US20100099766A1 (en) Topical NSAID compositions having sensate component
JP6666068B2 (ja) 外用組成物
RU2005136438A (ru) Применение ивермектина для лечения дерматологических расстройств
US20090022826A1 (en) Multi-step method of pain and/or inflammation treatment
JP2016515525A5 (me)
HK1213182A1 (zh) 外用药物组合物
ES2576740T3 (es) Composiciones farmacéuticas tópicas que incluyen REL-N-[6-[(2R,6S)-2,6-dimetil-4-morfolinil]-3-piridinil]-2-metil-4'-(trifluorometoxi)-[1,1'-bifenil]-3-carboxamida
TWI716394B (zh) 外用醫藥組合物
US20110237674A1 (en) Topical nsaid compositions having sensate component
JP7744739B2 (ja) アラントイン及び／又はその誘導体の安定化方法
ES2883956T3 (es) Composición oftálmica que comprende ácido lipoico y ácido hialurónico
JP2023108023A (ja) 外用組成物
CN106456598B (zh) 外用药物组合物
JP7751966B2 (ja) 外用組成物
JP5695310B2 (ja) γ−オリザノール含有外用剤組成物
CN100333722C (zh) 静脉用棓丙酯的稳定水包油乳剂及其制备方法
JP7446711B2 (ja) 皮膚外用組成物
WO2021203136A1 (en) Methods for treating hyperpigmentation and compositions for same
JP2021008450A (ja) 角層修復促進剤
JP6920031B2 (ja) 慢性角化型湿疹改善剤
JP7709827B2 (ja) 外用組成物
JP2014144929A (ja) ビタミン類を含有するニキビの予防又は治療用組成物
JP7356826B2 (ja) 外用組成物